Capricor Therapeutics Inc (NASDAQ:CAPR) shares are trading lower Friday afternoon after the biotech company reported a wider-than-expected fourth-quarter loss, even as it highlighted regulatory and clinical progress for its lead Duchenne muscular dystrophy candidate, deramiocel. Here’s what investors need to know.
- Capricor Therapeutics stock is feeling bearish pressure. Why are CAPR shares down?
Capricor Reports Wider-Than-Expected Q4 Loss
Capricor posted a quarterly loss of 62 cents per share, missing the consensus estimate of a 54-cent loss and worsening from a 16-cent loss in the prior-year period.
Investors appeared to focus on the earnings miss and the absence of quarterly revenue, which fell to zero from about $11.1 million a year earlier. Total operating expenses rose to roughly $29.2 million from $18.8 million, while fourth-quarter net loss widened to about $30.2 million from $7.1 million.
Capricor Says Phase 3 HOPE-3 Trial Met Primary Endpoint
Still, Capricor paired the weak earnings print with a bullish corporate update. The company said its biologics license application for deramiocel remains under FDA review, with a PDUFA target action date of Aug. 22.
It also said the Phase 3 HOPE-3 trial met its primary endpoint and a key secondary cardiac endpoint, while newly presented late-breaking data showed reductions in myocardial fibrosis, improved left ventricular ejection fraction in patients with baseline cardiomyopathy, and about 83% slowing of disease progression on a functional eating task.
Capricor ended 2025 with about $318.1 million in cash, cash equivalents and marketable securities and said that should fund operations through 2027.
Analysts Reaffirm Bullish Outlook on Capricor Stock
On the analyst front, HC Wainwright reiterated a Buy rating and maintained a $60 price target, while Piper Sandler reiterated Overweight and raised its price target to $58 from $45.
Capricor Shares Show Strong Bullish Momentum
Capricor Therapeutics shares have surged over the past year, climbing from a low of about $4.60 in late 2025 to a recent high near $33.57 as momentum strengthened in recent months.
The stock now trades well above its 20-, 50- and 200-day moving averages, signaling strong bullish momentum.
CAPR Shares Slide Friday Afternoon
CAPR Price Action: Capricor Therapeutics shares were down 5.69% at $31.52 at the time of publication on Friday, according to Benzinga Pro data.
Image: Adobe Stock Images
Recent Comments